

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**201280Orig1s000**

**MEDICAL REVIEW(S)**

**CLINICAL REVIEW**

**APPLICATION TYPE NDA**

**APPLICATION NUMBER(S) 201280**

**PRIORITY OR STANDARD S**

**SUBMIT DATE(S) JULY 2, 2010**

**RECEIVED DATE(S) JULY 2, 2010**

**PDUFA GOAL DATE MAY 2, 2011**

**DIVISION / OFFICE DIVISION OF METABOLISM  
AND ENDOCRINOLOGY  
PRODUCTS/OFFICE OF  
NEW DRUGS II**

**REVIEWER NAME(S) SOMYA VERMA DUNN**

**REVIEW COMPLETION DATE MARCH 11, 2011**

**ESTABLISHED NAME LINAGLIPTIN  
(PROPOSED) TRADE  
NAME**

**THERAPEUTIC CLASS**    **DIPEPTIDYL-PEPTIDASE  
INHIBITOR**

**APPLICANT**    **BOEHRINGER INGELHEIM  
PHARMACEUTICALS, INC.**

**FORMULATION(S)**    **ORAL TABLET**

**DOSING REGIMEN**    **5 MG DAILY**

**INDICATION(S)**    **TREATMENT OF TYPE 2  
DIABETES**

**INTENDED ADULTS  
POPULATION(S)**

Template Version: March 6, 2009

## Table of Contents

<b>CLINICAL REVIEW</b> .....	<b>1</b>
Table of Contents .....	3
Table of Tables .....	6
Table of Figures .....	10
<b>1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT</b> .....	<b>11</b>
1.1 Recommendation on Regulatory Action .....	11
1.2 Risk Benefit Assessment .....	11
1.3 Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ..	12
1.4 Recommendations for Postmarket Requirements and Commitments (PMRs and PMCs) .....	12
2.1 Product Information .....	14
2.2 Tables of Currently Available Treatments for Proposed Indications .....	15
2.3 Availability of Proposed Active Ingredient in the United States .....	16
2.4 Important Safety Issues With Consideration to Related Drugs .....	16
2.5 Summary of Presubmission Regulatory Activity Related to Submission .....	17
2.6 Other Relevant Background Information .....	18
<b>3 ETHICS AND GOOD CLINICAL PRACTICES</b> .....	<b>19</b>
3.1 Submission Quality and Integrity .....	19
3.2 Compliance with Good Clinical Practices (GCP) .....	19
3.3 Financial Disclosures .....	21
<b>4 SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES</b> .....	<b>25</b>
4.1 Chemistry Manufacturing and Controls .....	26
4.2 Clinical Microbiology .....	26
4.3 Preclinical Pharmacology/Toxicology .....	26
4.4 Clinical Pharmacology .....	27
4.4.1 Mechanism of Action .....	29
4.4.2 Pharmacodynamics .....	30
4.4.3 Pharmacokinetics .....	30
<b>5 SOURCES OF CLINICAL DATA</b> .....	<b>34</b>
5.1 Tables of Studies/Clinical Trials .....	34
5.2 Review Strategy .....	39
5.3 Discussion of Individual Studies/Clinical Trials .....	40
<b>6 REVIEW OF EFFICACY</b> .....	<b>40</b>
Efficacy Summary .....	40
6.1 Indication .....	40
6.1.1 Methods .....	40

6.1.2	Demographics .....	61
6.1.3	Subject Disposition.....	75
6.1.4	Analysis of Primary Endpoint(s) .....	84
6.1.5	Analysis of Secondary Endpoints(s) .....	104
6.1.6	Other Endpoints .....	115
6.1.7	Subpopulations .....	116
6.1.8	Analysis of Clinical Information Relevant to Dosing Recommendations ..	137
6.1.9	Discussion of Persistence of Efficacy and/or Tolerance Effects.....	137
6.1.10	Additional Efficacy Issues/Analyses .....	137
<b>7</b>	<b>REVIEW OF SAFETY.....</b>	<b>137</b>
	Safety Summary .....	137
7.1	Methods.....	137
7.1.1	Studies/Clinical Trials Used to Evaluate Safety .....	139
7.1.2	Categorization of Adverse Events .....	139
7.1.3	Pooling of Data Across Studies/Clinical Trials to Estimate and Compare Incidence.....	140
7.2	Adequacy of Safety Assessments .....	140
7.2.1	Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations .....	140
7.2.2	Explorations for Dose Response.....	142
7.2.3	Special Animal and/or In Vitro Testing .....	142
7.2.4	Routine Clinical Testing .....	142
7.2.5	Metabolic, Clearance, and Interaction Workup .....	142
7.2.6	Evaluation for Potential Adverse Events for Similar Drugs in Drug Class	142
7.3	Major Safety Results .....	142
7.3.1	Deaths.....	142
7.3.2	Nonfatal Serious Adverse Events .....	147
7.3.3	Dropouts and/or Discontinuations .....	150
7.3.4	Significant Adverse Events .....	152
7.3.5	Submission Specific Primary Safety Concerns .....	152
7.4	Supportive Safety Results .....	160
7.4.1	Common Adverse Events .....	160
7.4.2	Laboratory Findings .....	166
7.4.3	Vital Signs .....	179
7.4.4	Electrocardiograms (ECGs) .....	181
7.4.5	Special Safety Studies/Clinical Trials .....	182
7.4.6	Immunogenicity .....	191
7.6	Other Safety Explorations.....	191
7.5.1	Dose Dependency for Adverse Events .....	196
7.5.2	Time Dependency for Adverse Events.....	196
7.5.3	Drug-Demographic Interactions .....	197
7.5.4	Drug-Disease Interactions.....	201
7.5.5	Drug-Drug Interactions.....	201

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.